US20100216740A1 - Cereal-based Infant Nutrition with Fibre - Google Patents
Cereal-based Infant Nutrition with Fibre Download PDFInfo
- Publication number
- US20100216740A1 US20100216740A1 US12/532,583 US53258308A US2010216740A1 US 20100216740 A1 US20100216740 A1 US 20100216740A1 US 53258308 A US53258308 A US 53258308A US 2010216740 A1 US2010216740 A1 US 2010216740A1
- Authority
- US
- United States
- Prior art keywords
- cereal
- oligo
- fiber
- total
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000013339 cereals Nutrition 0.000 title claims abstract description 90
- 239000000835 fiber Substances 0.000 title claims description 113
- 235000021125 infant nutrition Nutrition 0.000 title description 4
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 95
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 94
- 239000002253 acid Substances 0.000 claims abstract description 67
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 192
- 239000000843 powder Substances 0.000 claims description 42
- 235000016709 nutrition Nutrition 0.000 claims description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 40
- 239000008103 glucose Substances 0.000 claims description 40
- 150000002482 oligosaccharides Polymers 0.000 claims description 37
- 229920001282 polysaccharide Polymers 0.000 claims description 37
- 239000005017 polysaccharide Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 150000004676 glycans Chemical class 0.000 claims description 35
- 235000013312 flour Nutrition 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 29
- 229920000294 Resistant starch Polymers 0.000 claims description 28
- 229920001542 oligosaccharide Polymers 0.000 claims description 28
- 235000021254 resistant starch Nutrition 0.000 claims description 28
- 229920002472 Starch Polymers 0.000 claims description 27
- 235000019698 starch Nutrition 0.000 claims description 27
- 239000008107 starch Substances 0.000 claims description 27
- 229920001277 pectin Polymers 0.000 claims description 22
- 239000001814 pectin Substances 0.000 claims description 22
- 235000010987 pectin Nutrition 0.000 claims description 22
- 235000019895 oat fiber Nutrition 0.000 claims description 17
- 229920001202 Inulin Polymers 0.000 claims description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 16
- 229940029339 inulin Drugs 0.000 claims description 16
- 235000021140 nondigestible carbohydrates Nutrition 0.000 claims description 16
- 230000035764 nutrition Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 244000062793 Sorghum vulgare Species 0.000 claims description 14
- 240000008042 Zea mays Species 0.000 claims description 14
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 14
- 240000007594 Oryza sativa Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 230000036186 satiety Effects 0.000 claims description 11
- 235000019627 satiety Nutrition 0.000 claims description 11
- 235000019713 millet Nutrition 0.000 claims description 10
- 244000075850 Avena orientalis Species 0.000 claims description 8
- 230000000291 postprandial effect Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 206010010774 Constipation Diseases 0.000 claims description 7
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 235000014966 Eragrostis abyssinica Nutrition 0.000 claims description 7
- 244000140063 Eragrostis abyssinica Species 0.000 claims description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 5
- -1 polysaccharides fructo-oligosaccharides Chemical class 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229940097362 cyclodextrins Drugs 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 2
- 235000021536 Sugar beet Nutrition 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims 5
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims 3
- 240000006394 Sorghum bicolor Species 0.000 claims 1
- 229940040387 citrus pectin Drugs 0.000 claims 1
- 239000009194 citrus pectin Substances 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 24
- 210000004251 human milk Anatomy 0.000 abstract description 23
- 235000005911 diet Nutrition 0.000 abstract description 15
- 230000037213 diet Effects 0.000 abstract description 15
- 239000007787 solid Substances 0.000 abstract description 9
- 230000007704 transition Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 235000013350 formula milk Nutrition 0.000 abstract description 7
- 239000008247 solid mixture Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 230000008901 benefit Effects 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 description 8
- 150000002402 hexoses Chemical group 0.000 description 8
- 235000009973 maize Nutrition 0.000 description 8
- 235000007319 Avena orientalis Nutrition 0.000 description 7
- 235000021055 solid food Nutrition 0.000 description 7
- 235000007558 Avena sp Nutrition 0.000 description 6
- 235000021128 adult diet Nutrition 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 229920002670 Fructan Polymers 0.000 description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 4
- 244000061456 Solanum tuberosum Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 230000001847 bifidogenic effect Effects 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 150000002772 monosaccharides Chemical group 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 240000006162 Chenopodium quinoa Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 206010021089 Hyporeflexia Diseases 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 244000081841 Malus domestica Species 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000001775 anti-pathogenic effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 235000011868 grain product Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 235000021129 infant diet Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000006198 methoxylation reaction Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 240000008570 Digitaria exilis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 235000019715 Fonio Nutrition 0.000 description 1
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000993813 Homo sapiens Protein inscuteable homolog Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 244000079423 Oxalis tuberosa Species 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 102100031729 Protein inscuteable homolog Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 240000003834 Triticum spelta Species 0.000 description 1
- 244000042038 Tropaeolum tuberosum Species 0.000 description 1
- 235000018963 Tropaeolum tuberosum Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 244000176766 Ullucus tuberosus Species 0.000 description 1
- 241000746966 Zizania Species 0.000 description 1
- 235000002636 Zizania aquatica Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000020627 health maintaining nutrition Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5116—Other non-digestible fibres
Definitions
- the present invention relates to the field of spoonable cereal-based infant nutrition.
- Fibres are of significant importance for a healthy nutrition. Some fibres have been described to improve bowel habit, intestinal flora, and gut barrier and prevent diarrhea or intestinal infections. Furthermore, oral intake of fibres increases satiety and blunts blood glucose fluctuations.
- Breast milk comprises, on average, about 10 g neutral oligosaccharides per litre and 1 g acidic oligosaccharides per litre.
- the adult diet includes a mixture of fibres, comprising soluble non-starch polysaccharides (including uronic acid carbohydrates), insoluble non-starch polysaccharides, non-digestible oligosaccharides, and resistant starch.
- the recommended fibre intake for an adult is about 30 g per day.
- an infant Upon the transition to solid food, an infant changes from a diet exclusively consisting of breast milk or liquid infant formula to a more mature diet. It is extremely important that the fibre component present in the adult nutrition is gradually introduced into the infant's diet. In this way the microflora and the colonic food is changed gradually, and gastrointestinal discomfort, such as bloating, abdominal pain, flatulence, diarrhea and constipation is avoided. Furthermore, during the transition from liquid to solid food, semi-liquid and/or semi-solid foods are preferred. These foods are preferably consumed with a spoon.
- “Milchbrei Apfel Karote” from Milupa (Germany) is a dry powder cereal product. After reconstitution with water, a spoonable cereal-based infant nutrition is formed comprising rice- and maize flour and apple and carrot powder.
- the present invention provides a semi-liquid and/or semi-solid cereal-based nutrition that is particularly suitable for supporting the transition period wherein the infant changes from a diet exclusively consisting of breast milk or liquid infant formula to mature, solid nutrition.
- the present composition is particularly designed to have the infant accustomed to fibre ingredients present in the adult diet.
- the cereal nutrition is of a semi-liquid and/or semi-solid constitution, with a viscosity of between 150 and 100,000 mPas. By providing nutrition with this viscosity an intermediate between liquid and solid food is provided. This enables the infant to get accustomed to eating in contrast to drinking only and enables the acquaintance with eating with a spoon. Solid food is still inappropriate for infants changing from breast milk or infant (liquid) formula, because of the infant's lack of teeth and its poor swallowing reflex.
- the present nutritional composition is adapted to meet the requirements of infants in the transition phase by providing a combination of a cereal component, an intermediate concentration of fibres and uronic acid carbohydrates with a degree of polymerisation (DP) of 10 to 300 monosaccharide units.
- a DP of 10 to 300 monosaccharide units is also herein referred to as medium, medium DP or medium chain carbohydrate.
- This DP is intermediate between the major acidic oligosaccharides found in human breast milk having a DP below 10, and the native, high DP pectin as found in the mature human nutrition, e.g. in the cell walls of vegetables and fruits, generally having a DP above 300.
- the present uronic acid carbohydrate with an intermediate DP has intermediate effects regarding the anti-pathogenic and bifidogenic effects of human milk acidic oligosaccharides and the blood glucose and satiety regulating effects of native pectin.
- medium DP pectin has advantageous product-technological properties, such as reduction of viscosity increasing effects and/or reduction of undesirable texturising effects, i.e. an unwanted mouthfeel effect compared to native pectin.
- This enables the inclusion of intermediate length uronic acid molecules in cereal products without a dramatic increase in viscosity. This is of utmost importance because these products usually already have a high viscosity and a further increase could result in an undesirable product.
- minimal or negligible increase in viscosity by addition of medium chain uronic acid molecules is remarkable since normally pectin forms rigid gels when combined with (calcium comprising) milk products.
- the present cereal-based nutritional composition By administering the present cereal-based nutritional composition, gastrointestinal discomfort, such as bloating, abdominal pain, flatulence, diarrhea and constipation is avoided.
- the present composition provides the advantages of fibres available in breast milk (such as anti-pathogenic and bifidogenic effects) and the advantages of fibres present in the adult diet (such as blood glucose and satiety regulating effects). It was found by the inventors that the cereal based nutrition of the present invention comprising a relatively small amount of fibre, attenuated blood glucose levels, despite the presence of a high concentration of glucose containing digestible carbohydrates.
- the present invention provides a nutritional composition with a viscosity at 20° C. and at a shear rate of 10 s ⁇ 1 between 150 and 100,000 mPas, comprising: 10 to 99 wt. % cereal component based on dry weight of the nutritional composition, 1.0 to 30 wt. % fibre based on dry weight of the nutritional composition, and 0.5 to 100 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre.
- the present invention provides a method for providing nutrition to an infant, said method comprising administering said nutritional composition to the infant.
- the present invention provides a method for regulation of blood glucose, decreasing post-prandial blood glucose levels, and/or prolonging the release of energy, said method comprising administering the present nutritional composition.
- the present invention provides a method for regulation of blood glucose, decreasing post-prandial blood glucose levels, and/or prolonging the release of energy, said method comprising administering the present fibre mixture comprising uronic acid carbohydrate with a degree of polymerisation of 10 to 300, inulin, resistant starch and oat fibre.
- the present invention provides a method for increasing satiety and/or improving sleep, said method comprising administering the present nutritional composition.
- the present invention provides a method for increasing satiety and/or improving sleep, said method comprising administering the present fibre mixture comprising uronic acid carbohydrate with a degree of polymerisation of 10 to 300, inulin, resistant starch and oat fibre.
- the present invention provides a method for treating and/or preventing constipation, diarrhea and/or gastro-intestinal infections said method comprising administering the present nutritional composition.
- the present invention also provides a process for the manufacture of a nutritional composition, comprising admixing a powder comprising: 10 to 99 wt. % cereal component based on dry weight of the powder, 1 to 30 wt. % fibre based on total dry weight of the powder, and 0.5 to 100 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre and a liquid.
- the present invention also provides a powder composition
- a powder composition comprising: 10 to 99 wt. % cereal flour, ground cereal and/or milled cereal based on dry weight of the powder composition, 1.0 to 30 wt. % fibre based on dry weight of the powder composition, and 0.5 to 100 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre.
- a more preferred embodiment is a powder composition comprising 20 to 90 wt. % cereal flour and/or milled cereals and/or ground cereals based on dry weight of the powder composition, 1.5 to 20 wt. % fibre based on dry weight of the powder composition, 0.5 to 86 wt.
- the present invention also concerns a nutritional composition
- a nutritional composition comprising a fibre mixture comprising 0.5 to 86 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre, 10 to 95 wt. % inulin based on total fibre, 2 to 80 wt. % resistant starch based on total fibre, and 2 to 80 wt. % oat fibre based on total fibre, the remaining of the powder being comprised of other components such as milk powder and/or powdered infant formula.
- the present invention also concerns a nutritional composition comprising a fibre mixture comprising 0.5 to 86 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre, 10 to 95 wt. % inulin based on total fibre, 2 to 80 wt. % resistant starch based on total fibre, and 2 to 80 wt. % oat fibre based on total fibre.
- the present invention provides a method for regulation of blood glucose, decreasing post-prandial blood glucose levels, and/or prolonging the release of energy, said method comprising administering the present fibre mixture comprising 0.5 to 86 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre, 10 to 95 wt. % inulin based on total fibre, 2 to 80 wt. % resistant starch based on total fibre, and 2 to 80 wt. % oat fibre based on total fibre.
- the present invention provides a method for increasing satiety and/or improving sleep, said method comprising administering the present fibre mixture comprising 0.5 to 86 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre, 10 to 95 wt. % inulin based on total fibre, 2 to 80 wt. % resistant starch based on total fibre, and 2 to 80 wt. % oat fibre based on total fibre.
- the present composition comprises a cereal component.
- Cereal components are an important part of the infant's diet, and are usually one of the first non-breast milk and non-infant formulae components introduced into the diet of infants.
- the infant will consume a high cereal diet, including bread, rice and pasta.
- the present cereal component preferably is a component selected from the group consisting of whole cereal, cereal flour, milled cereal, ground cereals, cereal starch, and cereal fibre.
- the present cereal component is preferably a component selected from the group consisting of cereal flour, ground cereal and milled cereal.
- the cereal flour preferably comprises cereal flour which is dextrinised by heat treatment and/or cereal flour which has been enzyme treated in order to degrade the cereal starch.
- the present composition comprises a precooked cereal component, more preferably precooked cereal flour.
- precooked cereal flour indicates flour obtained by the process whereby flour, in granular and crystalline structure is swelled and transformed, preferably in a continuous amorphous phase, in the presence of heat and water, dried (e.g.
- the precooked flour presently used preferably comprises between 5 and 15 wt. % protein based on the total dry weight of the precooked flour.
- the use of precooked flour has the further advantage that the final product has a reduced content of thermo-resistant spores compared to the use of non-precooked flour.
- the use of precooked flour in the present process has the advantage that the viscosity of the composition is more stable after reconstitution of the product with a warm liquid. This is in contrast to the situation wherein solely non-precooked flour is used. In the latter case the viscosity gradually increases with time.
- the precooked flour used in the present invention preferably has a degree of gelatinisation of at least 50%, preferably at least 75%. This gives better water holding capacity (WHC), resulting in an improved product (e.g. stability and palatability).
- WHC of the precooked material used in the present invention is preferably between 2 and 10 g water/g dry matter precooked material, more preferably between 2.5 and 5 g water/g dry matter precooked material.
- the WHC can be determined as described by Pinnavaia and Pizzirani (Starch/Stärke 50 (1998) nr. 2-3, S. 64-67).
- the present composition comprises at least one cereal selected from the group consisting of rice, millet, sorghum, wheat, barley, buckwheat, maize (corn), fonio, oats, quinoa, rye, triticale, teff, wild rice, spelt, amaranth, quinoa and starchy root crops.
- Starchy root crops are preferably selected from the group consisting of potato, sweet potato, cassaya, yams, aroids, oca, ulluco and mashua.
- the present composition is gluten free. The intake of gluten by infants below 6 month of age can result in gastro-intestinal damage.
- the present composition preferably comprises one or more cereal components selected from the group consisting of rice, maize and millet, sorghum, teff, oat and starchy root crops. More preferably, the present composition comprises one or more cereal components selected from the group consisting of rice, maize and millet, teff, and oat. More preferably the cereal component of the present composition consists of rice, maize and millet, sorghum, teff, oat, starchy root crops and mixtures thereof. More preferably the present cereal is selected from the group consisting of rice, maize, oat, teff and millet. Preferably the cereal part of the composition comprises mixtures of cereal components. Typically the cereal is processed as defined in EU directive 96/5/EC.
- the present composition preferably comprises between 10 and 99 g cereal component per 100 g dry weight of the present composition, more preferably between 20 and 90 g, even more preferably between 25 and 80 g.
- the term “fibre” as used in the present invention typically relates to all soluble non-digestible carbohydrates (SNC), insoluble non-starch polysaccharides (INSP), resistant starch and lignin.
- SNC soluble non-digestible carbohydrates
- INDP insoluble non-starch polysaccharides
- the present uronic acid carbohydrate is also a fibre.
- Uronic acid carbohydrates belong to the class of SNC.
- non-digestible as used in the present invention refers to carbohydrates which are not digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach) and reach the colon. Sugars such as lactose and sucrose are considered digestible.
- soluble when having reference to a carbohydrate, polysaccharide, fibre or oligosaccharide, means that the substance is at least 50% soluble according to the method described by L. Prosky et al., J. Assoc. Off. Anal. Chem. 71, 1017-1023 (1988).
- insoluble when having reference to a carbohydrate, polysaccharide, fibre or oligosaccharide, means that the substance is less than 50% soluble according to the method described by L. Prosky et al., J. Assoc. Off. Anal. Chem. 71, 1017-1023 (1988). For instance, an oat fibre being composed of 60 wt. % insoluble fibre and 40 wt. % soluble fibre is classified as insoluble fibre.
- the present nutritional composition comprises 1 to 30 wt. % fibre based on dry weight of the total composition, preferably 1.5 to 20 wt. %, more preferably 2 to 10 wt %.
- one serving of the present composition comprises 0.5 to 5 g fibre, more preferably 1 to 3 g fibre.
- Uronic acid carbohydrates are soluble, non-starch poly- and oligosaccharides.
- the term uronic acid carbohydrate as used in the present invention refers to a carbohydrate wherein at least 50% of the residues are selected from the group consisting of guluronic acid, mannuronic acid, galacturonic acid, glucuronic acid, riburonic, iduronic, N-acetylneuramic acid and neuramic acid.
- the term galacturonic acid carbohydrate as used in the present invention refers to a carbohydrate wherein at least 50% of the residues are galacturonic acid residues.
- the present nutritional composition preferably comprises 0.5 to 100 wt. % uronic acid carbohydrates with a DP of 10 to 300 based on total fibre, preferably at least 1 wt. %, more preferably at least 2 wt. %, even more preferably at least 5 wt. %.
- the composition comprises, of 0.01 to 30 wt. % uronic acid carbohydrate with a DP of 10 to 300 based on dry weight of the present composition, more preferably 0.05 to 10 wt. %, even more preferably 0.1 to 5 wt. %. More preferably, the present nutritional composition comprises 0.5 to 100 wt.
- % uronic acid carbohydrates with a DP of 20 to 200 based on total fibre, preferably at least 1 wt. %, more preferably at least 2 wt. %, even more preferably at least 5 wt. %.
- the composition comprises of 0.01 to 30 wt. % uronic acid carbohydrate with a DP of 20 to 200 based on dry weight of the present composition, more preferably 0.05 to 10 wt. %, even more preferably 0.1 to 5 wt. %.
- the present composition comprises preferably between 50 and 100 wt. % uronic acid carbohydrate with a DP of 10 to 300 based on total weight of uronic acid carbohydrates in the present composition, more preferably 75 to 100 wt. %.
- a sufficient amount of medium chain (DP of 10 to 300) uronic acid carbohydrates compared to short (DP ⁇ 10) and long (DP>300) carbohydrates ensures a proper transition to full length uronic acid molecules present in the mature diet.
- the uronic acid carbohydrate comprises at least 50% galacturonic acid residues based on total uronic acid residues in the uronic acid carbohydrate.
- the present composition comprises 25 to 100 wt. % galacturonic acid carbohydrates with a DP of 10 to 300, more preferably 20 to 300, based on total weight of uronic acid carbohydrates in the present composition.
- the uronic acid carbohydrates of the present invention comprises between 50 and 100 wt. % galacturonic carbohydrates with a DP of 10 to 300, more preferably 20 to 200, based on total weight of uronic acid carbohydrates.
- the present invention comprises at least 50 to 100 wt.
- % pectin molecules with a DP between 10 and 300, more preferably 20 to 200, based on total weight of uronic acid.
- Pectin frequently occurs in the adults diet, and hence advantageously medium chain (DP of 10 to 300) pectin is used in the present composition.
- the present composition preferably comprises less than 25 wt. % of the uronic acid carbohydrates with a DP above 300, more preferably above 200, based on total weight of uronic acid carbohydrates.
- the present composition preferably comprises less than 25 wt. % uronic acid carbohydrates with a DP below 10, more preferably below 20, based on total weight of uronic acid carbohydrates.
- At least one of the terminal hexose units of the uronic acid carbohydrate has a double bond, which is preferably situated between the C 4 and C 5 position of the terminal hexose unit.
- one of the terminal hexose units comprises the double bond.
- the double bond at terminal hexose unit can for example be obtained by enzymatically degrading pectin with lyase.
- at least 5%, more preferably at least 10%, even more preferably at least 25% of the terminal hexose units of the uronic acid carbohydrate is an unsaturated hexose unit.
- each individual uronic acid carbohydrate preferably comprises only one unsaturated terminal hexose unit, preferably less than 50%, more preferably less than 40% of the terminal hexose comprises a double bond.
- the uronic acid carbohydrate may be esterified, such as acetylated, methylated, methoxylated and/or amidated.
- the uronic acid carbohydrates are preferably characterised by a degree of esterification, preferably methoxylation, below 70%, preferably below 50%, more preferably below 30%.
- a low degree of esterification advantageously results in easier fermentation by the intestinal flora and/or an increased anti-adhesive effect on pathogenic bacteria.
- the uronic acid carbohydrates have a degree of esterification, preferably methoxylation above 20%, preferably above 50% even more preferably above 60%.
- the uronic acid carbohydrates have a degree of methylation above 10%, preferably above 20%, preferably above 50% even more preferably above 70%.
- a high degree of esterification advantageously increases the bioavailability of cations, preferably calcium, iron and/or magnesium.
- the present uronic acid carbohydrate has a viscosity of below 50 mPas, preferably below 30 mPas at a 2 wt. % solution in water at 25° C. and a shear rate of 10 s ⁇ 1 .
- Suitable methods to obtain medium DP uronic acid carbohydrates are described in Van Deventer-Schriemik & Pilnik, 1987, Acta Alimentaria 16:143-153.
- a preferred source of uronic acid carbohydrates is partially degraded alginate or partially degraded pectin from citrus fruits, apples, and/or sugar beet, more preferably partially degraded pectin from apple.
- a preferred source of the present uronic acid carbohydrate is modified citrus pectin. Modified citrus pectin is preferably obtained by lysis to smaller molecular weight molecules by treatment at pH 10 and at a pH of 3 for a longer period of time.
- Modified citrus pectin is comprised of linear polygalacturonate chains comprising from 5 to 90 galacturonic acid residues, with an average of approximately 55 residues. Modified citrus pectin is also known as modified pectin, depolymerised pectin and pH-modified pectin. Another preferred source of uronic acid carbohydrate is ultra low viscosity pectin which is partially degraded, such as Herbapekt SF 50 LV (Herbafood) or ultralow viscosity pectin from Obipektin.
- the present composition preferably further comprises soluble, non-digestible carbohydrates other than uronic acid carbohydrates (hereinafter abbreviated to SNC).
- SNC soluble, non-digestible carbohydrates other than uronic acid carbohydrates
- the present composition comprises a soluble non-digestible carbohydrate selected from the group consisting of galacto-oligo- and/or polysaccharide (including transgalacto-oligo- and/or polysaccharides), xylo-oligo- and/or polysaccharide, gluco-oligo- and/or polysaccharide (including gentio-oligosaccharides, malto-oligosaccharides, isomalto-oligosaccharides, resistant dextrins and cyclodextrins), arabino-oligo- and or polysaccharide, mannan-oligo- and/or polysaccharide, galactomanno-oligo- and/or polysaccharides, glucomanno-oli
- SNC particularly galactooligosaccharides
- a healthy microflora, and particularly a healthy Bifidobacteria count is important when infants start consuming a more mature diet, which normally comprises more pathogens than breast milk and infant nutrition.
- the bifidogenic factors as present in breast milk should be maintained in the diet in order to induce a gradual change of the intestinal flora.
- the present composition preferably contains a SNC with a DP between 2 and 200, more preferably a DP between 2 and 100, more preferably a DP between 2 and 50.
- a lower DP of the SNC improves the fermentability by the intestinal flora and reduces viscosity of the final product.
- the present composition comprises at least 5 wt. % SNC based on total fibre, more preferably at least 10 wt. %.
- the SNC has the additional advantage that it gives good product characteristics, e.g. the soluble fibres do not precipitate and are as good as inert towards other ingredients of the present composition.
- the composition comprises preferably less than 95 wt. % SNC based on total fibre.
- the present composition preferably comprises 0.05 to 25 g SNC per 100 g dry weight of the composition, preferably 0.1 to 10 g, more preferably 0.5 to 5 g.
- the present composition preferably comprises at least a galacto-oligosaccharide.
- These oligosaccharides are the same or highly similar to the galactose-based oligosaccharides present in human milk.
- the present composition comprises a galaco-oligosaccharides are selected from the group consisting of ⁇ -galactooligosaccharides (including raffinose and stachyose), sialylated and/or fucosylated galactooligosaccharides (including sialyllactose and fucosyllactose), lacto-N-tetraose (LNT) and lacto-N-neotetraose (neo-LNT).and ⁇ -galactooligosaccharides.
- the saccharides of the galacto-oligosaccharide are ⁇ -linked, as is the case in human milk.
- the present invention comprises the administration of transgalacto-oligosaccharide with a DP below 10.
- Transgalacto-oligosaccharides These are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands), Oligomate 55 (Yakult), CupOligo (Nissin), or Bimmuno (Clasado).
- the present composition preferably comprises 0.05 to 9 g of the galacto-oligosaccharide per 100 g dry weight of the composition, more preferably 0.1 to 2 g, even more preferably 0.2 to 1 g.
- the present composition comprises a fruit-, vegetable- or cereal-based neutral, soluble, non-digestible carbohydrate, preferably a fructan.
- a fructan preferably a maltan.
- the present composition preferably comprises fructans.
- the term “fructans” as used herein refers to an oligosaccharide or polysaccharide comprising a chain of at least 2 ⁇ -linked fructose units, with a DP between 2 and 100, preferably between 20 and 60.
- inulin is used. In inulin the fructose units are linked with a ⁇ (2 ⁇ 1) linkage.
- Inulin is for instance available under the tradename “Raftilin HP®”, (Orafti).
- the inulin has at least 90% glucose-terminated fructose chains.
- the average DP of the present fructan is preferably at least 9, more preferably at least 15, more preferably at least 20.
- the present composition preferably comprises 0.05 to 9 g of the vegetable-, fruit- and/or cereal-derived soluble non-digestible non-starch carbohydrate per 100 g dry weight of the composition, more preferably 0.1 to 2 g, even more preferably 0.2 to 1 g.
- the present nutrition comprises both the galacto-oligosaccharides (for the human milk resemblance) and the fruit-, vegetable- or cereal-based neutral, soluble, non-digestible carbohydrate (as part of the adult diet).
- an increased diversity of neutral soluble non-starch non-digestible carbohydrates stimulates a wider population of beneficial intestinal bacteria over a prolonged length of time in the colon.
- the weight ratio galacto-oligosaccharides: vegetable-, fruit- and/or cereal-based neutral, soluble, non-starch, non-digestible carbohydrates is 49:1 to 1:49, more preferably 19:1 to 1:19, even more preferably 9:1 to 1:9, most preferably 3:1 to 1:3.
- the present composition comprises insoluble, non-digestible carbohydrates (INC).
- IOC insoluble, non-digestible carbohydrates
- the present composition comprises between 0.1 and 7.5 g INC per 100 g dry weight, more preferably between 0.2 and 3 g, even more preferably between 0.3 and 1 g.
- the present composition comprises is 5 to 95 wt. % INC based on total fibre, more preferably 10 to 50 wt. %, even more preferably 10 to 25 wt. %.
- the present composition contains resistant starch.
- Resistant starch is an INC that provides substrate for the colon over a prolonged period of time. Upon fermentation of resistant starch, high concentrations of butyrate are formed, which are also is found in higher concentrations in the adult colon. Butyrate has a beneficial effect on the gut barrier integrity. Hence, the butyrate content in the infant's intestine needs to be gradually increased to mature levels. Furthermore, the inclusion of resistant starch blunts blood glucose levels.
- the present composition comprises 0.01 to 5 g resistant starch per 100 g dry weight of the present composition, more preferably 0.02 to 2 g, even more preferably 0.05 to 1 g.
- the resistant starch is derived from cereals. The amount of resistant starch in the composition can be determined by the method described by AOAC 2002.02 and AACC 37; McCleary BV & Monaghan DA (2002) Measurement of resistant starch. Journal of AOAC International 85, 665-675.
- the resistant starch is selected from starch derived from a cereal selected from the group consisting of rice, maize and millet.
- a suitable source for resistant starch is HI Maize 1043 from National Starch which is derived from maize.
- the present composition comprises 2 to 80 wt. % resistant starch based on total fibre, more preferably 5 to 40 wt. %, even more preferably 10 to 20 wt. %.
- the present composition further comprises insoluble non-starch polysaccharides (hereinafter abbreviated to INSP).
- INSP insoluble non-starch polysaccharides
- the present composition comprises 0.02 to 5 g INSP per 100 g dry weight of the present composition, more preferably 0.05 to 2 g, even more preferably 0.1 to 1 g.
- the present composition comprises 5 to 80 wt. % INSP based on total fibre, more preferably 10 to 40 wt. %, even more preferably 10 to 20 wt. %.
- the INSP is selected from the group consisting of cellulose, insoluble soy polysaccharides and hemi-cellulose.
- the cellulose and/or hemicellulose used in the present composition is purified from oat, rice, millet, corn, bamboo, and/or potatoes, most preferably oat.
- the INSC is selected from the group consisting of oat fibre, rice fibre, corn fibre, potato fibre, bamboo fibre and millet fibre, most preferably oat fibre.
- the oat fibre may alternatively be a soluble non-digestible carbohydrate.
- the present composition comprises a mixture of resistant starch and INSP, Preferably the composition comprises a mixture of resistant starch and oat fibre.
- the digestible carbohydrates in the present composition provide 30 to 90% of the total energy content, preferably 40 to 80%.
- the present composition preferably comprises a combination of lactose, and digestible plant-derived carbohydrates. Lactose is the main carbohydrate source in infant milk while digestible plant carbohydrates are a main source of carbohydrates in the adult diet. The combination of lactose and digestible plant-derived carbohydrate supports the transition period.
- the present composition preferably comprises less than 15 wt. % monosaccharide based on total weight of digestible carbohydrate, preferably less than 10 wt. %, most preferably less than 5 wt. %.
- the present composition preferably comprises between 40 and 70 wt. % disaccharide based on total weight of digestible carbohydrate, including at least 10 wt. % lactose based on total weight of digestible carbohydrate, preferably at least 40 wt. % lactose.
- the lactose content does not exceed 70 wt.
- the lactose content does not exceed 60 wt. %.
- the present composition may e.g. include sucrose and/or maltose.
- a high content of lactose is included as disaccharide, since it results in attenuated blood glucose levels.
- digestible starch and/or maltodextrin are present.
- digestible starch is cereal-derived.
- the digestible starch comprises slowly digestible starch. Slowly digestible starch is defined as starch which is converted to glucose between 20 and 120 minutes during in vitro digestion as described by Englyst et al 1992. Eur. J. Clin. Nutr.
- the composition comprises at least 10 wt. % slowly digestible starch based on total digestible starch, more preferably at least 20 wt. %, even more preferably at least 30 wt. %.
- the amount of slowly digestible starch does not exceed 70 wt. % based on total digestible starch.
- the protein in the present composition provides 5 to 16% of the total energy of the present composition, more preferably 8 to 12%.
- the present composition comprises a protein selected from the group consisting of casein, whey, (skim) milk protein, soy protein, pea protein, collagen, rice protein, millet protein, teff protein, sorghum protein, potato protein and corn protein.
- the present transition nutrition preferably comprises a combination of animal protein and cereal protein.
- the weight ratio animal milk protein: cereal protein is preferably 1:10 to 10:1.
- the fat in the present composition preferably provides 1 to 40% of the total energy, more preferably 15 to 35%, even more preferably 20 to 30%.
- the amount of saturated fatty acids is preferably below 58 wt. % based on total fatty acids, more preferably below 45 wt. %.
- the concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids.
- the concentration of polyunsaturated fatty acids in the present composition is preferably between 11 and 36% based on weight of total fatty acids.
- the fats are highly advantageous for the growth of the infant.
- the essential fatty acids linolenic acid (LA; an omega 6 fatty acid) and ⁇ -linolenic acid (ALA; an omega 3 fatty acid) preferably are present in sufficient amounts and in a balanced ratio, since LA and ALA deficiency and/or imbalance impair growth.
- the present composition preferably comprises 1.8 to 12.0 wt. % LA based on dry weight of the composition, and at least 0.30 wt. % ALA based on dry weight of the composition.
- the weight ratio LA/ALA is preferably between 5 and 15.
- the present composition comprises long chain polyunsaturated fatty acids (LC-PUFA), more preferably eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA).
- LC-PUFA provide a further acquaintance to ingredients in solid food, and more importantly, provide the infant with appropriate components for a good neurological development.
- the present composition preferably has an increased caloric density compared to human milk and/or liquid infant formula, which is a further step towards solid nutrition. It is also important that the present composition does not have an excessive caloric density. Hence, preferably the caloric density is between 200 and 700 kcal/100 g dry weight, even more preferably between 300 and 600 kcal/100 g, most preferably between 350 and 500 kcal/100 g.
- the present composition preferably comprises 5 to 16% protein; 1 to 40% fat; and 30 to 90% digestible carbohydrates based on total calories, more preferably 8 to 12% protein, 15 to 35% fat and 50 to 75% digestible carbohydrates. In other words the present composition preferably comprises comprising 5 to 16 en.
- % protein 30 to 90 en. % digestible carbohydrate and 1 to 40 en. % fat, more preferably 8 to 12 en. % protein, 50 to 75 en. % digestible carbohydrate and 15 to 35 en. % fat.
- en. % is short for energy percentage and represents the relative amount each constituent contributes to the total caloric value of the composition.
- the present nutritional composition is particularly suitable for feeding to an infant because it provides the infant with the required nutrients.
- the composition comprises vitamins, minerals and/or trace elements.
- the composition comprises 3 to 10 mg iron per 100 g dry weight.
- the iron suitably prevent anaemia.
- Zinc stimulates the immune system, preparing the infant for a more mature diet.
- the present composition preferably comprises 50 to 150 ⁇ g iodine per 100 g dry weight. This prevents iodine deficiency disorders.
- the present composition preferably comprises 300 to 500 mg calcium per 100 g dry weight of the composition. This improves bone health.
- the standard diet of infants aged 4 to 24 months is usually low in iron, iodine and zinc.
- the present composition also solves the above problems which sometimes occur when the infant switches for breast milk to a more mature diet.
- the present composition has a viscosity of between 150 and 100,000 mPas at 20° C. and at a shear rate of 10 s ⁇ 1 , preferably between 250 and 25,000 mPas, more preferably between 300 and 10,000 mPas, even more preferably between 500 and 10,000 mPas, most preferably between 1000 and 10,000 mPas.
- the present composition preferably has a semi-liquid and/or semi-solid constitution. Solid food is still inappropriate for infants changing from breast milk or infant liquid, because of the infant's lack of teeth and its poor swallowing reflex.
- Semi-liquid in the present invention refers to food products that have a viscosity above 150 mPas, but are still pourable.
- Semi-solid in the present invention refers to products that are still formable or spreadable but not pourable, with a viscosity up to 100,000 mPas.
- viscosity refers to the physical parameter which is determined according to the following method: Shear flow viscosities were determined in a Paar Physika MCR 300 Modular Compact Rheometer. The instrument was equipped with a concentric cylinder geometry with a diameter of 27 mm. A logarithmic shear rate ramp is used from 0.1 to 1000 s ⁇ 1 in 20 minutes having 40 measurement points. Using the same geometry viscosities can also be measured in shear flow at a constant shear rate of 10 s ⁇ 1 for 10 minutes. The rheometer's thermostat is set on the appropriate temperature (i.e. 20° C.).
- the osmolarity of the semi-liquid and/or semi-solid nutrition of the invention is preferably between 300 and 600 mOsm/1, more preferably between 400 and 500 mOsm/1.
- the composition is in a ready-to-eat form, in which the liquid is already present.
- This has the advantage that the product needs only to be heated before consumption and has a stable viscosity during consumption.
- the present composition is preferably present in the form of granules, flakes, puffs and/or shreds, more preferably granules.
- the present composition also relates to a powder composition
- a powder composition comprising: 10 to 99 wt. % cereal based on dry weight of the powder composition; 1.0 to 30 wt. % fibre based on dry weight of the powder composition; and 0.5 to 100 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre.
- Reconstitution of this powder with a liquid preferably water or milk
- a liquid preferably water or milk
- a viscosity of between 150 and 100,000 mPas.
- 10 to 100 g powder is reconstituted with 140 ml liquid (preferably water), more preferably 14 to 80 g powder, even more preferably 30 to 65 g powder, most preferably 40 to 60 g is reconstituted with 140 ml liquid.
- the liquid has a temperature of 30-70° C. upon mixing with the powder.
- the present invention encompasses a packaging containing the present powder composition, wherein the packaging indicates that the powder composition is to be mixed with a suitable amount of liquid.
- the powder is in an agglomerated and/or granulated form with an average particle size below 2 mm, more preferably below 1 mm.
- the composition comprises milk protein, calcium, lactose and fat.
- the dried product can be reconstituted with water instead of milk. Water advantageously is more readily available and less prone to contamination than milk.
- the fat is of vegetable origin. This has the advantage that a healthier product is obtained than when the dried product is reconstituted with cow's milk comprising more saturated fat.
- the present composition is particularly useful for feeding human infants.
- the present composition is particularly suitable for feeding infants having the age of 4 to 36 months, more preferably having an age of 4 to 18 months, even more preferably having an age of 4 to 8 months, since that is the age by which the diet of the infant is starting to change.
- gastrointestinal discomfort such as bloating, abdominal pain, flatulence, diarrhea and constipation are avoided, while providing in transition both the advantages of fibres available in breast milk and the advantages of fibres for adults.
- the present fibre mixture comprising medium chain uronic acid carbohydrates is preferably composed in such a way that it enables a graduate change from the fibres present in breast milk to the fibres present in the mature diet.
- This fibre mixture is intermediate between the breast milk fibres and mature diet fibres both in quality as in quantity.
- the present composition can also suitably be used as clinical nutrition, for sick humans with a fragile intestinal tract. Hence in one embodiment the present composition is used in a method for providing nutrition to elderly and/or hospitalised patients.
- the composition of the invention is used prevent and/or treat diarrhea and/or to prevent and/or treat intestinal infections.
- the present composition has this effect because of the beneficial effects of the fibre composition of the invention on the intestinal flora and/or the preventive effect on colon adhesion by pathogens.
- the present composition comprises a soluble non-digestible carbohydrate selected from the group consisting of galactooligosaccharides, fructooligosaccharides and/or fructopolysaccharides.
- the composition of the invention is used to prevent and/or treat constipation. Because of the water holding capacity and/or the effects on the intestinal flora of the fibre composition of the invention, the stool frequency is increased and/or the stools have a softer consistency, thereby preventing and/or treating constipation.
- the fibre mixture of the present invention slows emptying of the stomach and slows the release of glucose into the blood and/or absorption of glucose in the small intestine.
- nutritional composition of the present invention comprising the fibre mixture including medium chain uronic acid carbohydrate is used to attenuate blood glucose and/or insulin levels, prolong the provision of energy, prolong the feeling of satiety, and/or improve sleep by reducing feelings of hunger.
- the present invention is used to regulate blood glucose levels.
- the present invention is used to reduce the post-prandial blood glucose increase.
- the present invention is used to prolong the feeling of satiety. Similar terminology may be used on the packages such as reducing glycaemic index, and/or slower release of glucose into the blood.
- the present invention provides process for the manufacture of a nutritional composition, comprising admixing a) a powder comprising: 10 to 99 wt. % cereal based on dry weight of the powder; 1 to 30 wt. % based fibre based on total dry weight of the powder; and 5 to 100 wt. % uronic acid carbohydrate with a degree of polymerisation of 10 to 300 based on total fibre; and b) liquid.
- the mixing process preferably yields the present nutritional composition as described above.
- Blood glucose values (mmol/l) after consumption of cereal comprising 25 g available carbohydrate with ( ⁇ ) or without ( ⁇ ) a fibre mixture comprising oat fibre, medium chain pectin, inulin and resistant starch.
- a dry composition comprising skimmed milk powder, demineralised whey powder, vegetable fat, rice flour and ground corn, glucose, fructose, maltodextrin, fibre mixture, others (minerals, trace elements, vitamins flavours).
- composition comprises 67.9 g digestible carbohydrates per 100 g:
- composition comprises 2.2 g of the dietary fibre mixture per 100 g:
- composition comprises 1.1 g fibre present in the cereal component. 26 g of the powder is reconstituted with 75 ml water, yielding about 100 ml. The viscosity at 20° C. and at a shear rate of 10 s ⁇ 1 at is about 8500 mPas
- the cereal composition of example 1 reconstituted with water, comprising 25 g available, digestible carbohydrate and 1.2 g fibre (0.87 g deriving from the fibre mixture, 0.435 g fibre deriving from the cereal component) or a similar cereal composition but without the fibre mixture, reconstituted with water, comprising 25 g available, digestible carbohydrate and 0.435 g fibre deriving from the cereal.
- IAUC Average Incremental Area under the curve
- the cereal mixture of the present invention comprising the fibre mixture can be classified as a low GI food. The results are surprising since even in the presence of a high amount of glucose containing digestible carbohydrates, a relatively small amount of fibre was able to blunt blood glucose levels. These results are indicative for the beneficial effect of the present invention on regulation of blood glucose, decreasing post-prandial blood glucose levels, and/or prolonging the release of energy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pediatric Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Dairy Products (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2007/050121 WO2008115046A1 (en) | 2007-03-22 | 2007-03-22 | Cereal-based infant nutrition with fibre |
PCT/NL2008/050165 WO2008115062A1 (en) | 2007-03-22 | 2008-03-21 | Cereal-based infant nutrition with fibre |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100216740A1 true US20100216740A1 (en) | 2010-08-26 |
Family
ID=38704962
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/532,583 Abandoned US20100216740A1 (en) | 2007-03-22 | 2008-03-21 | Cereal-based Infant Nutrition with Fibre |
US13/914,009 Abandoned US20130273195A1 (en) | 2007-03-22 | 2013-06-10 | Cereal-based infant nutrition with fibre |
US15/168,369 Active 2028-09-03 US10440982B2 (en) | 2007-03-22 | 2016-05-31 | Cereal-based infant nutrition with fibre |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/914,009 Abandoned US20130273195A1 (en) | 2007-03-22 | 2013-06-10 | Cereal-based infant nutrition with fibre |
US15/168,369 Active 2028-09-03 US10440982B2 (en) | 2007-03-22 | 2016-05-31 | Cereal-based infant nutrition with fibre |
Country Status (9)
Country | Link |
---|---|
US (3) | US20100216740A1 (de) |
EP (1) | EP2124624B1 (de) |
CN (1) | CN101677601B (de) |
AU (1) | AU2008227241B2 (de) |
CA (1) | CA2681715C (de) |
MY (1) | MY149567A (de) |
NZ (1) | NZ580338A (de) |
RU (1) | RU2460319C2 (de) |
WO (2) | WO2008115046A1 (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140024580A1 (en) * | 2007-12-05 | 2014-01-23 | N.V. Nutricia | High energy liquid enteral nutritional composition |
US9420816B2 (en) | 2008-03-12 | 2016-08-23 | N.V. Nutricia | High protein liquid enteral nutritional composition |
US20180200189A1 (en) * | 2015-07-07 | 2018-07-19 | Perora Gmbh | Method of inducing satiety |
CN108697142A (zh) * | 2016-01-26 | 2018-10-23 | 雀巢产品技术援助有限公司 | 用于控制婴儿或幼儿的食物摄入量和生长的包含2FL和LNnT的组合物 |
US10821124B2 (en) * | 2015-03-05 | 2020-11-03 | Societe Des Produits Nestle S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
CN114401642A (zh) * | 2019-09-18 | 2022-04-26 | 科汉森母乳低聚糖股份有限公司 | 含有人乳寡糖的谷物组合物 |
US11311570B2 (en) | 2014-08-11 | 2022-04-26 | Perora Gmbh | Method of inducing satiety |
US20220151279A1 (en) * | 2019-08-05 | 2022-05-19 | Mizkan Holdings Co., Ltd. | Powdery food containing edible plant, and food/drink containing same |
US11504330B2 (en) | 2014-08-11 | 2022-11-22 | Perora Gmbh | Formulation comprising particles containing a water-swellable or water-soluble polymeric component and a lipid component |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2153734A1 (de) * | 2008-07-24 | 2010-02-17 | IPC Process-Center GmbH & Co. KG | Nahrungsergänzungsmittel sowie Verfahren zu dessen Herstellung |
US20110293784A1 (en) | 2010-05-28 | 2011-12-01 | Anja Wittke | Milk-based nutritional compositions |
BR112012023328A2 (pt) * | 2010-05-28 | 2016-08-23 | Mead Johnson Nutrition Co | composições nutricionais |
CN102488133B (zh) * | 2011-11-14 | 2013-01-09 | 深圳市味奇生物科技有限公司 | 一种婴幼儿米粉及其制备方法 |
ES2552249T1 (es) * | 2012-04-17 | 2015-11-26 | The Procter & Gamble Company | Aparato dosificador de líquidos |
WO2014007606A1 (en) * | 2012-07-05 | 2014-01-09 | N.V. Nutricia | Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour |
US20150296851A1 (en) * | 2012-11-27 | 2015-10-22 | Shanghai Jiao Tong University | Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof |
WO2016036234A1 (en) * | 2014-09-01 | 2016-03-10 | N.V. Nutricia | Staged food products for infants and children |
CN104872506A (zh) * | 2015-04-23 | 2015-09-02 | 亳州市中信食品有限责任公司 | 一种添加猴菇营养成分的米粉 |
US20190142055A1 (en) * | 2016-03-31 | 2019-05-16 | Tuttifoodi B.V. | Granules |
AU2017251143B2 (en) | 2016-04-11 | 2021-05-20 | Société des Produits Nestlé S.A. | Infant nutrition delivering metabolic benefits |
WO2019055717A1 (en) * | 2017-09-13 | 2019-03-21 | Evolve Biosystems, Inc. | OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN |
EP3813533A4 (de) * | 2018-06-26 | 2021-05-19 | Bahçesehir Üniversitesi | Funktioneller brotstick |
WO2020120223A1 (en) * | 2018-12-13 | 2020-06-18 | Société des Produits Nestlé S.A. | Powdered thickener maintaining its extensional properties when reconstituted and for promoting safe swallowing by individuals with dysphagia |
CN110122864B (zh) * | 2019-06-03 | 2021-12-24 | 哈尔滨工业大学 | 调节断乳期婴幼儿肠道菌群的即食辅助食品及其制备方法 |
MX2022007918A (es) * | 2019-12-23 | 2022-07-27 | Cargill Inc | Composiciones de harina de arroz soluble. |
WO2022171569A1 (en) * | 2021-02-10 | 2022-08-18 | Firmenich Sa | Fiber blends, sweetened fiber blends, and their comestible use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260279A (en) * | 1990-10-24 | 1993-11-09 | Sandoz Ltd. | Enteral nutrition and medical foods having soluble fiber |
US5472952A (en) * | 1993-03-18 | 1995-12-05 | Bristol-Myers Squibb Company | Partially hydrolyzed pectin in nutritional compositions |
US20030118712A1 (en) * | 2001-12-20 | 2003-06-26 | Navarro Y Koren Peter Antonio | Matrix-forming composition containing pectin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE308254T1 (de) * | 1998-12-15 | 2005-11-15 | Nestle Sa | Ballaststoffemischung für enterale zusammensetzung |
US6248375B1 (en) * | 2000-03-14 | 2001-06-19 | Abbott Laboratories | Diabetic nutritionals and method of using |
CN1261039C (zh) * | 2002-04-26 | 2006-06-28 | 徐铁龙 | 营养保健谷物食品 |
US6890571B2 (en) * | 2002-05-14 | 2005-05-10 | National Starch And Chemical Investment Holding Corporation | Slowly digestible starch product |
CN1874690B (zh) * | 2003-09-03 | 2011-06-08 | 荷兰联合利华有限公司 | 增加饱足感的食物组合物 |
EP1634599A1 (de) * | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Immunstimulierende Kindernahrung |
EP1714660A1 (de) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronsäure und Probiotika |
-
2007
- 2007-03-22 WO PCT/NL2007/050121 patent/WO2008115046A1/en active Application Filing
-
2008
- 2008-03-21 US US12/532,583 patent/US20100216740A1/en not_active Abandoned
- 2008-03-21 CN CN200880014299.9A patent/CN101677601B/zh active Active
- 2008-03-21 AU AU2008227241A patent/AU2008227241B2/en not_active Ceased
- 2008-03-21 CA CA2681715A patent/CA2681715C/en not_active Expired - Fee Related
- 2008-03-21 RU RU2009138931/13A patent/RU2460319C2/ru not_active IP Right Cessation
- 2008-03-21 NZ NZ580338A patent/NZ580338A/en not_active IP Right Cessation
- 2008-03-21 EP EP08723916A patent/EP2124624B1/de active Active
- 2008-03-21 WO PCT/NL2008/050165 patent/WO2008115062A1/en active Application Filing
- 2008-03-21 MY MYPI20093951A patent/MY149567A/en unknown
-
2013
- 2013-06-10 US US13/914,009 patent/US20130273195A1/en not_active Abandoned
-
2016
- 2016-05-31 US US15/168,369 patent/US10440982B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260279A (en) * | 1990-10-24 | 1993-11-09 | Sandoz Ltd. | Enteral nutrition and medical foods having soluble fiber |
US5260279B1 (en) * | 1990-10-24 | 1997-05-20 | Sandoz Ltd | Nutritional composition comprising hydrolyzed guar gum |
US5472952A (en) * | 1993-03-18 | 1995-12-05 | Bristol-Myers Squibb Company | Partially hydrolyzed pectin in nutritional compositions |
US20030118712A1 (en) * | 2001-12-20 | 2003-06-26 | Navarro Y Koren Peter Antonio | Matrix-forming composition containing pectin |
Non-Patent Citations (5)
Title |
---|
Definition of "compound" and "composition" from the Grant & Hackh's Chemical Dictionary (1987) p. 148, McGraw-Hill, Inc. * |
Gibson, G.R., Fuller, R. (2000) Aspects of In Vitro and In Vivo Research Approaches Directed Toward Identifying Probiotics and Prebiotics for Human Use. The Journal of Nutrition, vol. 130, no. 2S, p. 391S-395S. * |
Mongeau, R., Brassard, R. (1982) Determination of Neutral Detergent Fiber in Breakfast Cereals: Pentose, Hemicellulose, Cellulose and Lignin Content. Journal of Food Science, vol. 47, p. 550-555. * |
Oli, M.W., Petschow, B.W., Buddington, R.K. (1998) Evaluation of Fructooligosaccharide Supplementation of Oral Electrolyte Solutions for Treatment of Diarrhea. Digestive Diseases and Sciences, vol. 43, no. 1, p. 138-147. * |
Ramakrishna, B.S., Venkataraman, S., Srinivasan, P., Dash, P., Young, G.P., Binder, H.J. (2000) Amylase-Resistant Starch Plus Oral Rehydration Solution for Cholera. The New England Journal of Medicine, vol. 342, no. 5, p. 308-313. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140024580A1 (en) * | 2007-12-05 | 2014-01-23 | N.V. Nutricia | High energy liquid enteral nutritional composition |
US8999423B2 (en) * | 2007-12-05 | 2015-04-07 | N. V. Nutricia | High energy liquid enteral nutritional composition |
US9345256B2 (en) | 2007-12-05 | 2016-05-24 | N.V. Nutricia | High energy liquid enteral nutritional composition |
US9420816B2 (en) | 2008-03-12 | 2016-08-23 | N.V. Nutricia | High protein liquid enteral nutritional composition |
US11311570B2 (en) | 2014-08-11 | 2022-04-26 | Perora Gmbh | Method of inducing satiety |
US11504330B2 (en) | 2014-08-11 | 2022-11-22 | Perora Gmbh | Formulation comprising particles containing a water-swellable or water-soluble polymeric component and a lipid component |
US10821124B2 (en) * | 2015-03-05 | 2020-11-03 | Societe Des Produits Nestle S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
US20180200189A1 (en) * | 2015-07-07 | 2018-07-19 | Perora Gmbh | Method of inducing satiety |
US11234935B2 (en) * | 2015-07-07 | 2022-02-01 | Perora Gmbh | Method of inducing satiety |
CN108697142A (zh) * | 2016-01-26 | 2018-10-23 | 雀巢产品技术援助有限公司 | 用于控制婴儿或幼儿的食物摄入量和生长的包含2FL和LNnT的组合物 |
US20220151279A1 (en) * | 2019-08-05 | 2022-05-19 | Mizkan Holdings Co., Ltd. | Powdery food containing edible plant, and food/drink containing same |
CN114401642A (zh) * | 2019-09-18 | 2022-04-26 | 科汉森母乳低聚糖股份有限公司 | 含有人乳寡糖的谷物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2681715C (en) | 2015-06-16 |
CN101677601B (zh) | 2014-03-12 |
US20130273195A1 (en) | 2013-10-17 |
US20170027216A1 (en) | 2017-02-02 |
US10440982B2 (en) | 2019-10-15 |
AU2008227241B2 (en) | 2013-03-14 |
RU2460319C2 (ru) | 2012-09-10 |
MY149567A (en) | 2013-09-13 |
RU2009138931A (ru) | 2011-04-27 |
EP2124624B1 (de) | 2013-02-13 |
CN101677601A (zh) | 2010-03-24 |
EP2124624A1 (de) | 2009-12-02 |
WO2008115046A1 (en) | 2008-09-25 |
WO2008115062A1 (en) | 2008-09-25 |
AU2008227241A1 (en) | 2008-09-25 |
NZ580338A (en) | 2012-07-27 |
CA2681715A1 (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10440982B2 (en) | Cereal-based infant nutrition with fibre | |
EP2230943B1 (de) | Pädiatrische ballaststoffmischung | |
US20120201922A1 (en) | Liquid transition nutrition for infants | |
ZA200504385B (en) | Prebiotic compositions | |
Meyer et al. | Inulin | |
Śliżewska et al. | Resistant dextrins as prebiotic | |
Ambuja et al. | Review on “dietary fiber incorporated dairy foods: a healthy trend” | |
US6737414B2 (en) | Composition for enteral nutrition comprising fibres | |
Kuthiala et al. | Benefits of functional oligosaccharides (FOS) in treating functional bowel disorders (FBD) and low caloric substitutes for diabetics | |
RU2375920C2 (ru) | Жидкое переходное питание для младенцев | |
Jahan et al. | Dietary Fiber as 10 | |
EP4454471A1 (de) | Pulver für säuglingsnahrung mit verbesserten fliesseigenschaften | |
CN113905742A (zh) | 保持健康体重或减轻体重的非治疗性方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: N.V. NUTRICIA, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STAHL, BERND;ALLES, MARTINE SANDRA;BORGMANN, BRIGITTE ANTONIA MARIA;REEL/FRAME:027848/0247 Effective date: 20091207 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |